FDA approves regorafenib (Stivarga) for metastatic colorectal cancer

Oncology (Williston Park). 2012 Oct;26(10):896.
No abstract available

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / pathology
  • Drug Approval*
  • Humans
  • Phenylurea Compounds / therapeutic use*
  • Pyridines / therapeutic use*
  • Survival Rate
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration

Substances

  • Antineoplastic Agents
  • Phenylurea Compounds
  • Pyridines
  • regorafenib